Edition:
United States

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

615.15INR
6:27am EDT
Change (% chg)

Rs8.20 (+1.35%)
Prev Close
Rs606.95
Open
Rs615.00
Day's High
Rs621.95
Day's Low
Rs611.15
Volume
1,348,799
Avg. Vol
1,419,269
52-wk High
Rs994.00
52-wk Low
Rs567.80

Select another date:

Mon, Sep 18 2017

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for desonide ointment, 0.05 pct

* Says Glenmark Pharmaceuticals receives ANDA approval for desonide ointment, 0.05% Source text - http://bit.ly/2w3Zohv Further company coverage:

BRIEF-Glenmark pharmaceuticals seeks shareholders' nod for re-appointment of Glenn Saldanha as chairman & MD

* Seeks shareholders' nod for re-appointment of Glenn Saldanha as the chairman & managing director Source text - http://bit.ly/2x4lXHk Further company coverage:

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for ointment to treat skin inflammation

* Says receives ANDA approval for triamcinolone acetonide ointment usp, 0.1% Source text for Eikon: Further company coverage:

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for acyclovir ointment USP, 5 pct

* Says Glenmark Pharmaceuticals receives ANDA approval for acyclovir ointment USP, 5% Source text - http://bit.ly/2w4yYgk Further company coverage:

BRIEF-Glenmark Pharmaceuticals reports positive data in phase 2A study of GBR 830 for treatment of patients with atopic dermatitis

* Glenmark Pharmaceuticals reports positive data in a phase 2A study of GBR 830 for the treatment of patients with atopic dermatitis

BRIEF-India's Glenmark Pharmaceuticals June qtr consol profit up about 47 pct

* June quarter consol profit 3.33 billion rupees versus profit of 2.27 billion rupees last year

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for Desonide cream​

* Says ‍receives anda approval for Desonide cream, 0.05%​ Source text: http://bit.ly/2uS13tc Further company coverage:

BRIEF-Glenmark pharmaceuticals enters exclusive agreement with Cyndea Pharma S.L.

* Entered into a development, license, manufacture and commercial supply agreement with Cyndea Pharma S.L.

Fitch Revises Glenmark's Outlook to Stable; Affirms at 'BB'

(The following statement was released by the rating agency) SINGAPORE/MUMBAI, July 14 (Fitch) Fitch Ratings has revised Glenmark Pharmaceuticals Ltd's (Glenmark's) Outlook to Stable from Positive, and affirmed the Long-Term Issuer Default Rating (IDR) at 'BB'. The agency also affirmed the rating on Glenmark's USD200 million 4.50% senior unsecured notes due 2021 at 'BB'. The revision in the Outlook reflects Fitch's expectation that Glenmark's free cash flow will be largely neutral over the next t

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for hypertension treating tablets

* Says Glenmark Pharmaceuticals receives ANDA approval for amlodipine and olmesartan medoxomil tablets Source text for Eikon: Further company coverage:

Select another date: